– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering –– Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers –– Launch Date Accelerated by One Month at Health Care Providers Request – ANN ARBOR, Mich., June 04, 2020 (GLOBE NEWSWIRE)…

Read More

The past few months we have faced unprecedented times across the globe. The recent events, including ongoing episodes of racism and violence, underscore the urgency for us to prioritize inclusion, amplify marginalized voices, and continue to shine a light on cardiovascular health issues that affect so many. Cardiovascular disease does not discriminate by race, color,…

Read More

Esperion has announced that NEXLETOL™ (bempedoic acid) is now available in pharmacies in the United States. NEXLETOL is an oral, once-daily, tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. To…

Read More

March 25, 2020, Jacksonville, FL – The American Society for Preventive Cardiology (ASPC) launches the American Journal of Preventive Cardiology, one of the only journals dedicated solely to preventive cardiology in the U.S.  “Preventive cardiology has witnessed exponential growth over the past few decades in the available clinical tools and new knowledge. We are excited…

Read More

The Million Hearts® is now taking applications for its Hospitals & Health Systems Recognition Program. The Program acknowledges institutions working to systematically improve the cardiovascular health of the population and communities they serve. Institutions can apply now through April 30, 2020 and will be among the first to be considered for the Hospitals & Health…

Read More